Sept 17 (Reuters) - Eli Lilly ( LLY ) has established

itself as the market leader in obesity drugs in markets in

Europe, Asia and the Middle East and expects to replicate its

U.S. dominance in all markets, the company's international

president told Reuters on Wednesday.

Patrik Jonsson, Lilly's Executive Vice President for markets

outside the U.S., told Reuters that the drugmaker is using a

consumer-focused commercial strategy similar to its approach in

the United States, including partnerships with telehealth and

digital platforms to reach patients who are overwhelmingly

paying for weight-loss drugs out-of-pocket, from Britain to

China to the United Arab Emirates.

(Reporting by Maggie Fick and Mrinalika Roy; Editing by Ros

Russell)